Us Food and Drug Administration extends action date for dapagliflozin by three months
PRINCETON, NJ & WILMINGTON, DE, USA I October 26, 2011 I Bristol-Myers Squibb Company and AstraZeneca announced today that the US Food and Drug Administration has extended the action date for dapagliflozin for the treatment of type 2 diabetes by three months.
New anticoagulant dabigatran has a significantly higher rate of complications than warfarin when used in a real-world setting, a new analysis concludes.